{"product_id":"spondyloarthritis-research-and-treatment-network-23rd-spartan-annual-meeting-2025","title":"Spondyloarthritis Research and Treatment Network 23rd SPARTAN Annual Meeting 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: rheumatologists and immunologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e1. Overview\u003c\/p\u003e\n\u003cp\u003e2. Learning Objectives\u003c\/p\u003e\n\u003cp\u003eAnalyze the pathophysiological mechanisms of Spondyloarthritis, including the roles of HLA-B27, T cells, and spatial gene profiles.\u003c\/p\u003e\n\u003cp\u003eEvaluate individualized treatment options and the safety of emerging therapies like CAR-T and NSAIDs in adult and pediatric SpA patients.\u003c\/p\u003e\n\u003cp\u003eApply advanced MRI protocols and physical exam techniques to accurately diagnose and monitor radiographic progression in axial SpA.\u003c\/p\u003e\n\u003cp\u003eAssess the latest ACR-SPARTAN-SAA clinical guidelines and outcome measures, such as BASDAI, in managing psoriatic arthritis and SpA.\u003c\/p\u003e\n\u003cp\u003eIdentify the unique clinical manifestations, sex-gender differences, and comorbidities, particularly Inflammatory Bowel Disease, associated with SpA.\u003c\/p\u003e\n\u003cp\u003e3. Target Audience\u003c\/p\u003e\n\u003cp\u003eBest for rheumatologists and immunologists who want updates on spondyloarthritis pathophysiology, advanced imaging, and targeted therapies.\u003c\/p\u003e\n\u003cp\u003e4. Topics\u003c\/p\u003e\n\u003cp\u003eDay 1 Classification and Clinical Manifestation of SpA- Deep Dive into IBP – Soha Dolatabadi, MD\u003c\/p\u003e\n\u003cp\u003eDay 1 IBD and SpA – Reem Jan, MD, MBBS\u003c\/p\u003e\n\u003cp\u003eDay 1 Individualize axSpA Treatment Options a Case Based Discussion- Lianne Gensler, MD\u003c\/p\u003e\n\u003cp\u003eDay 1 MRI Workshop- Protocol, Finding, and Mimickers – Dennis Poddubnyy, MD, PhD, MSc\u003c\/p\u003e\n\u003cp\u003eDay 1 Sex-Gender differences in Presentation and Manifestations of SpA – Lihi Eder, MD, PhD\u003c\/p\u003e\n\u003cp\u003eDay 1 Slowing Radiographic Progression in Axial SpA – Marina Magrey, MD\u003c\/p\u003e\n\u003cp\u003eDay 1 SpA Physical Exam Workshop – Philip Mease, MD\u003c\/p\u003e\n\u003cp\u003eDay 2 Basic Science – Ruth Napier, PhD\u003c\/p\u003e\n\u003cp\u003eDay 2 CLASSIC – Walter Maksymowych, MD, FRCP, FACP, University of Alberta, Alberta\u003c\/p\u003e\n\u003cp\u003eDay 2 Clinical Science and Imaging – Jean Liew, MD, MS\u003c\/p\u003e\n\u003cp\u003eDay 2 Clinical Trials – Abhijeet Danve, MBBS, MD, FACP\u003c\/p\u003e\n\u003cp\u003eDay 2 IBD and SpA – Reem Jan, MD, MBBS\u003c\/p\u003e\n\u003cp\u003eDay 2 Neuroimaging of Pain in Ankylosing Spondylitis Karen D. Davis, PhD, FCAHS, FRSC, Professor, Department of Surgery …\u003c\/p\u003e\n\u003cp\u003eDay 2 SPARTAN Research Career Achievement and Distinguished Service Award Presentations\u003c\/p\u003e\n\u003cp\u003eDay 2 T cells AS Patients – Michael Paley, MD, PhD\u003c\/p\u003e\n\u003cp\u003eDay 3 ACR-SPARTAN-SAA Guidelines – Liron Caplan, MD, PhD\u003c\/p\u003e\n\u003cp\u003eDay 3 BASDAI and its Components as Outcome Measures for axPsA – Pankti Mehta, MD, MBBS\u003c\/p\u003e\n\u003cp\u003eDay 3 BASIS – Sibel Aydin, MD\u003c\/p\u003e\n\u003cp\u003eDay 3 Imaging – Denis Poddubnyy, MD, PhD, MSc\u003c\/p\u003e\n\u003cp\u003eDay 3 MRI neg axSpA does not exist – Lianne Gensler, MD, Atul Deodhar, MD\u003c\/p\u003e\n\u003cp\u003eDay 3 New Pediatric SpA Classification Criteria – Pamela Weiss, MD, MSCE\u003c\/p\u003e\n\u003cp\u003eDay 3 Safety of Prescription NSAIDs in Adults with IBD- Data from a Large Administrative Claims Cohort – Adam Mayer, MD\u003c\/p\u003e\n\u003cp\u003eDay 3 Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis – Steven Dang\u003c\/p\u003e\n\u003cp\u003eDay 3 Spatial Gene Profiles for New Bone Formation in Ankylosing Spondylitis – Akihiro Nakamura, MD, PhD\u003c\/p\u003e\n\u003cp\u003eDay 3 The Deubiquitinase TRABID is a Novel Therapeutic Target in Spondyloarthritis – Archita Srinath\u003c\/p\u003e\n\u003cp\u003eGroup Day 1\u003c\/p\u003e\n\u003cp\u003eGroup Day 2\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405819039940,"sku":null,"price":99.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Spondyloarthritis-Research-and-Treatment-Network-23rd-SPARTAN-Annual-Meeting-2025.jpg?v=1784216589","url":"https:\/\/medicalcoursespro.com\/products\/spondyloarthritis-research-and-treatment-network-23rd-spartan-annual-meeting-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}